Malignant Lymphoma
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Disease confirmed malignant lymphoma 2 Patients must be more than 18 years old and less than 65 years old 3 We don't care prior therapy 4 It will be expected to have neutropenia more than grade 3 after treatment with chemotherapy 5 Patients must receive pegfilgrastim in prior therapy before starting this study 6 Performance status is less than 2 7 Life expectancy more than 3 months without chemotherapy 8 Written informed consent must be obtained prior to any screening procedures
Exclusion criteria
Exclusion criteria: 1 Patients must not have any allergy with pegfilgrastim or filgrastim in the past 2 Pregnant or nursing women 3 SpO2 less than 94%: room air 4 Cardiac dysfunction: LVEF<50% 5 Liver dysfunction, Renal dysfunction ALT more than 5*ULN T.Bil more than 5*ULN sCr more than 2*ULN 6 HIV1/2 infection 7 Uncontrolled mental disease 8 Uncontrolled hypertension 9 Uncontrolled diabetes 10 Uncontrolled infectious disease 11 Dual malignancy 12 Patients were judged unqualified for this study by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Actual number of CD34 positive stem cells after pegfilgrastim injection | — |
Countries
Japan
Contacts
Public ContactHideki Goto
Hokkaido University Hospital Department of Hematology
Outcome results
None listed